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Abstract
Background—Although combination antiretroviral therapy continues to evolve, with potentially
more effective options emerging each year, the ability of therapy to prevent multiple regimen
failure and mortality in clinical practice remains poorly defined.
Methods—Sixteen cohorts representing over 60 sites contributed data on all individuals who
initiated combination antiretroviral therapy. We identified those individuals who experienced
virologic failure (defined as a human immunodeficiency virus [HIV] RNA level >1000 copies/
mL), received modified therapy, and subsequently had a second episode of virologic failure.
Multivariate Cox regression was used to assess factors associated with time to second regimen
failure and the time to death after the onset of second regimen failure.
Results—Of the 42,790 individuals who received therapy, 7159 experienced a second virologic
failure. The risk of second virologic failure decreased from 1996 (56 cases per 100 person-years)
through 2005 (16 cases per 100 person-years; P < .001). The cumulative mortality after onset of
second virologic failure was 26% at 5 years and decreased over time. A history of AIDS, a lower
CD4+ T cell count, and a higher plasma HIV RNA level were each independently associated with
mortality. Similar trends were observed when analysis was limited to the subset of previously
treatment-naive patients
Conclusions—Although the rates of multiple regimen failure have decreased dramatically over
the past decade, mortality rates for those who have experienced failure of at least 2 regimens have
remained high. Plasma HIV RNA levels, CD4+ T cell counts at time of treatment failure, and a
history of AIDS remain independent risk factors for death, which emphasizes that these factors
remain important targets for those in need of more-aggressive therapeutic interventions.
Although most patients enrolled in clinical trials are able to achieve durable suppression of
human immunodeficiency virus (HIV) replication, a significant proportion of patients in
clinical practice did not achieve such a response, at least to their first regimen [1]. The
degree to which patients who have experienced failure of a first regimen are at risk for
subsequent failure has not been well studied, in part because few cohorts have followed up
enough patients to address this question.
The overall clinical impact of virologic failure is poorly defined. A number of studies have
shown that patients who are unable to achieve and maintain an undetectable viral load do
well clinically and immunologically, compared with those who do not receive therapy [2–4].
In clinical practice, treatment failure appears to be an uncommon cause of mortality [5–8].
Among patients with drug-resistant infection, those with more mutations do not necessarily
do worse than those with only a limited number of mutations [9], although other studies
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have reported that those with multidrug failure or multidrug resistance have an overall poor
prognosis, compared with those who experience more limited drug failure [10–14].
Because of the uncertainties regarding the overall incidence and clinical consequences of
multiple regimen failure, we analyzed data from an established collaboration of US and
Canadian cohorts (North American AIDS Cohort Collaboration on Research and Design;
NA-ACCORD). We first investigated the incidence and predictors of progression to
virologic failure after receipt of at least 2 combination antiretroviral regimens. We next
investigated the rates and predictors of mortality after the onset of a second virologic failure.
We focused on failure of 2 regimens, because most HIV-infected individuals in resource-




The data for this study were collected as part of the North American AIDS Cohort
Collaboration on Research and Design (NA-ACCORD), part of the International
Epidemiological Databases to Evaluate AIDS project [15]. The NA-ACCORD was
established in 2006 as a regional collaboration of existing single-site and multisite cohorts
from the United States and Canada. The participating cohorts have been approved by local
institutional review boards and use standardized methods of data collection. Seventeen
cohorts contributed data for this study. This included 5 interval cohort studies, in which
enrollment is targeted and the timing and content of data collection are part of research
studies at prespecified intervals. The other 12 cohorts were based in clinical settings, where
the timing and type of data collected is determined by the nature of the health care services
provided by the center.
For the current analysis, we identified those individuals who met the following inclusion
criteria: (1) age >18 years, (2) initiation of first regimen prior to or while participating in
follow-up in the cohort, (3) experience of an initial episode of virologic failure while
receiving a standard regimen, (4) modification of therapy after first virologic failure, and (5)
provision of a CD4+ T cell count within 1 year before regimen change. Information on
pregnancy or use of investigational antiretroviral agents was not available.
Study definitions
A combination antiretroviral treatment regimen was defined as containing at least 3
antiretroviral drugs. One of these drugs had to have been a protease inhibitor (PI) or a
nonnucleoside reverse-transcriptase inhibitor (NNRTI), unless the regimen contained 3
nucleoside reverse-transcriptase inhibitors (NRTIs) that included abacavir or tenofovir. We
excluded individuals who received the combination of zidovudine and stavudine.
Virologic failure was defined by at least 1 plasma HIV RNA measurement >1000 copies/mL
measured >3 months after therapy initiation. A therapy modification after first virologic
failure was defined as a switch in the nonnucleoside analogue component of the regimen
(eg, a switch from an NNRTI to a PI, a switch from a PI to an NNRTI, a switch from an
unboosted PI to ritonavir-boosted PI, or a switch from a triple–nucleoside analogue regimen
to a regimen including an NNRTI or a PI).
Data analysis
This study had 2 overall objectives: to define the incidence and predictors of second
virologic failure over time and to determine the rates and predictors of mortality after second
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virologic failure. For the first objective, our study sample included individuals who started
an initial regimen, exhibited evidence of virologic failure, and subsequently modified
therapy. Follow-up time began when therapy modification was observed, and it extended to
the time of either second virologic failure or the last contributed HIV RNA measurement.
Subjects were included in this analysis even if they modified therapy after the initial
regimen change and before experiencing a second failure. Person-time was allocated to the
calendar time of observation in annual intervals (1996 and 1997 were combined because of
small numbers of patients, with annual intervals through 2005) for computation of incidence
rates. Cohort-stratified Cox regression models were used to identify factors associated with a
second treatment failure. Calendar time contributions were time-varying using left-
truncation methods. All other predictors occurred at or prior to therapy modification and
included demographic factors, clinical factors, initial regimen type, and whether individuals
were antiretroviral experienced at the time that the first regimen was initiated. With this
model, age was accounted for as a cubic spline term with 5 knots. Assessment of hepatitis C
virus infection was available for most (86%) of the patients. A history of injection drug use
(IDU), however, was available for only ~40% of patients.
For the mortality objective, we developed a prognostic model using an “intention-to-treat”
approach that ignored all treatment changes after the development of second treatment
failure. Cox regression models, stratified by cohort with left-truncation methods, were
constructed to determine the association of demographic and clinical factors prior to or at
the time of second regimen failure. Follow-up ended at the month of death, 1.5 years after
the date of the last CD4+ cell count measurement, or on 31 December 2005, whichever
occurred first.
For each analysis, we first included all patients, regardless of prior treatment experience, and
then we analyzed separately those patients who were antiretroviral-naive before initiation of
their first combination regimen. We also investigated the sensitivity of the models to
influence from individual cohorts by examining estimates calculated with data from each
cohort systematically omitted from the analyses.
RESULTS
Seventeen cohorts that represented >60 sites contributed data on 36,188 HIV-infected
individuals who initiated therapy. Of these individuals, 17,820 were identified as having
experienced an initial episode of virologic failure, 13,165 had a regimen change after the
first virologic failure and provided at least 1 CD4+ T cell count within 1 year prior to the
regimen change and at least 1 HIV RNA level after the regimen change (Figure 1). The
median duration of time between first virologic failure and the time that therapy was
modified was 0.5 years (interquartile range [IQR], 0.2–1.2 years). The median CD4+ cell
count at the time of the switch increased from 170 to 293 cells/mm3 with calendar time,
whereas the plasma HIV RNA level decreased from 27,470 to 4300 copies/mL (Table 1).
The majority of patients who experienced a first regimen failure were receiving a protease
inhibitor regimen, although the prevalence of protease inhibitor use decreased from 92% to
48% of patients with calendar time, whereas NNRTI use increased from 6% to 38%. The
majority of patients had exposure to mono- or dual-nucleoside reverse-transcriptase
analogues before receipt of the first standard combination regimen, although the prevalence
of prior antiretroviral exposure decreased from 90% to 37% of patients over calendar time.
We also analyzed outcomes for the 19,876 subjects who were treatment naive at the time
that their first standard combination regimen was initiated. Of these patients, 5087 exhibited
an initial episode of virologic failure after switching to a second regimen, and 2289
exhibited evidence of a second virologic failure. The median duration of time between the
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first virologic failure and therapy modification was 0.42 years (IQR, 0.17–1.08). At the time
of the switch to a second regimen, the median CD4+ T cell count was 175 cells/mm3 and the
median plasma HIV RNA level was 9716 copies/mL.
Incidence of multiple regimen failure
Of the 13,165 patients who switched to a second regimen, 7159 subsequently exhibited
evidence of virologic failure. At the time of second virologic failure, the median CD4+ T
cell count was 244 cells/mm3 (IQR, 120–405 cells/mm3), and the median plasma HIV RNA
level was 13,000 copies/mL (IQR, 3100–60,864 copies/mL). Most patients (66%) had been
exposed to all 3 classes at the time of the second treatment failure. The risk of experiencing
a second virologic failure decreased dramatically during the first decade that these regimens
were available (P < .001; Figure 2). The crude incidence of second treatment failure during
1996–1997 was 56 (95% confidence interval [CI], 50–63) events per 100 person-years. This
incidence decreased to 16 (95% CI, 14–18) events per 100 person-years in 2005. In the
cohort-stratified multivariate Cox regression analysis, these temporal trends remained strong
and statistically significant (Table 2). The trends remained of similar magnitude and
significance when the outcomes were censored after the first year of the second regimen.
Similar trends were observed in the subset of 5087 patients who were treatment naive before
receipt of their first regimen and who eventually modified therapy after an initial episode of
virologic failure. The crude incidence of second regimen failure among this subset during
1996–1997 was 40 (95% CI, 26–62) events per 100 person-years. This incidence decreased
to 18 (95% CI, 15–21) events per 100 person-years in 2005.
Predictors of multiple regimen failure
We identified additional factors associated with experiencing a second treatment failure after
regimen switch (Table 2). After adjusting for calendar time, a longer time between the
initiation and modification of therapy and a higher CD4+ cell count were associated with a
lower risk of second treatment failure. Both a higher viral load at the first virologic failure
time point and a higher viral load at the time that the regimen was switched were associated
with an increased risk of second treatment failure. As expected, these 2 viral load
measurements were highly correlated (ρ = 0.57). When included together in the same model,
only the preswitch viral load was independently associated with a second viral failure (Table
2). Neither sex, age, history of AIDS, or initial regimen type was associated with second
treatment failure in multivariate analysis. These predictors remained of similar magnitude
when the outcomes were censored at 1 year after regimen switch and when the analysis was
restricted to those who were antiretroviral naive before receipt of their first regimen. The
analyses of data that left out each cohort systematically provided estimates that were
generally within the presented confidence limits.
We also investigated the 2 components of the time from therapy initiation to therapy
modification; namely, the time from therapy initiation to first virologic failure (or the
duration of success) and the time from first virologic failure to therapy modification. After
adjusting for the other factors in Table 2, each of these variables was statistically
significantly (P < .001) associated with a second virological failure when added to the model
separately. When included together in a model, only the time from treatment initiation to
first virologic failure was statistically significantly associated with a lower risk of second
virologic failure (hazard ratio [HR], 0.90 per year; P < .001).
Among those with data available, both hepatitis C virus infection and IDU were associated
with a shorter time to second virological failure (HR, 0.90 and 0.95, respectively), but only
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hepatitis C virus infection was statistically significant (P < .01). These variables did not
materially impact the inferences of the other variables in the model.
Similar trends were observed in the subset of 5087 patients who were treatment naive before
receipt of their first regimen (Table 2). In this subset, however, the calendar time trend was
attenuated and not statistically significant (P = .29). After adjusting for calendar time, a
higher CD4+ T cell count at the time of the first regimen switch was associated with a lower
risk of second regimen failure. Both a higher plasma HIV RNA level at the first virologic
failure time and a higher plasma HIV RNA level at the time that the regimen was switched
were independently associated with an increased risk of second treatment failure.
In our primary analysis, only a singe viral load >1000 copies/mL was necessary to meet our
failure definition. Most individuals who had a follow-up viral load determined at 3, 6, or 12
months after their virologic failure time point had a confirmatory viral load (82%, 84%, and
88% of patients, respectively). Censoring individuals who did not have a confirmatory
virologic failure did not materially impact the results.
Mortality after second virologic failure
Of the 7159 subjects who experienced a second regimen failure, 6698 had >1 month of
follow-up after second treatment failure and had data on all covariates. There were 1532
deaths observed during 25,722 person-years of follow-up after second treatment failure. The
cumulative mortality was 5% at 1 year and 26% at 5 years (Figure 3). The crude incidence
of mortality among those who experienced a second regimen failure during 1996–1997 was
6.5 (95% CI, 5.4–8.0) per 100 person-years. This incidence decreased to a low of 5 deaths
per 100 person-years among those who experienced a second regimen failure beginning in
2003. In multivariate analysis, there was a statistically significant trend towards lower risk
of death among those with second treatment failure in later years (P < .01; Table 3).
Of the 2050 patients who had no treatment experience before the initiation of combination
therapy and who experienced a second regimen failure, 355 died. The crude incidence of
mortality among those who experienced a second regimen failure in 1998 was 7.0 (IQR,
4.8–10.3) deaths per 100 person-years. This incidence decreased to 3.0 (IQR, 1.4–6.3)
deaths per 100 person-years among those who experienced a second regimen failure in
2004; this trend remained statistically significant (P = .01; Table 3).
Predictors of mortality after second virologic failure
In addition to the calendar time trends noted above, a lower CD4+ cell count at the time of
second virologic failure, a higher viral load at the time of a second virologic failure, and a
history of AIDS at the time of second virologic failure were each strongly associated with a
greater risk of mortality (Table 3). Sex, pretherapy CD4+ cell count, pretherapy viral load,
and regimen type were not associated with mortality in multivariate analysis.
Data on hepatitis C virus infection and a history of IDU were available in a subset of
patients. Both variables were associated with a greater risk of mortality (HR, 1.66 and 1.42
for hepatitis C virus infection and IDU, respectively; P < .01for each). However, neither of
these variables materially changed the inferences from the analyses displayed in Table 3.
Furthermore, the analyses of data that left out each cohort systematically provided estimates
that were generally within the presented confidence limits.
These predictors of mortality remained of similar magnitude and significance when the
analysis was restricted to those individuals who were antiretroviral treatment naive before
receipt of their first regimen (Table 3). Both hepatitis C virus infection and a history of IDU
had similar relative hazard magnitudes (1.48 and 1.13) as that observed in the entire cohort;
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the effect of hepatitis C virus infection remained statistically significant (P < .01), but a
history of IDU did not achieve statistical significance (P = .74).
DISCUSSION
The overall objective of this study was to define the incidence and long-term consequences
of multiple regimen failure among treated individuals across North America. The overall
incidence of second virologic failure decreased dramatically, eventually reaching a stable
level in 2005 of ~16 cases per 100 person-years for the entire cohort and 18 cases per 100
persons-years for those patients who were treatment naive at the time that their first
combination regimen was initiated. The risk of mortality after a second regimen failure was
high (5–6.5 deaths per 100 person-years; as a comparison, among the larger NA-ACCORD
population of all treatment-naive patients starting therapy, the crude death rates were 1.3–1.6
deaths per 100 person-years) [16]. Although there was evidence that the mortality rates
among those patients who experienced multiple regimen failures decreased over time, the
rate of decrease was modest, compared with the far more dramatic improvements in risk of
progressing to second regimen failure. Collectively, these data indicate that the effectiveness
of combination therapy continues to improve, even among those patients who experienced
failure of an initial regimen. However, among those who experience virologic failure of at
least 2 distinct regimens, the overall clinical prognosis remains poor.
The ability of an initial antiretroviral regimen to durably suppress virus replication in
clinical practice has increased with time [17–20], presumably in part as a result of the
greater potency and tolerability of current regimens, compared with those used in the earlier
time period. Our data extend these observations to those who had experienced failure of an
initial regimen and were switched to a subsequent regimen. The dramatic decreases in the
rate of failure of these second line regimens is likely attributable to several factors, including
improved therapeutic options (ie, more-potent and better-tolerated regimens), as well as
improved therapeutic strategies (ie, initiation of therapy earlier in the disease course), and
perhaps better monitoring of patients who are receiving therapy [8,21–24].
The major strength of our study is the large sample size and the inclusion of cohorts
representing a diverse population of patients and a diverse selection of health care delivery
systems. Our approach, however, has certain limitations that deserve comment. First, the
observation periods ended in 2005, just prior to the introduction of several drugs with
proven efficacy in highly treatment-experienced patients. One of the most important
questions in the field is whether the efficacy of darunavir, raltegravir, maraviroc, and
etravirine, which was observed in clinical trials, will translate into comparable levels of
effectiveness when used more broadly [25–27]. A second limitation pertains to the lack of
consistent data on important covariates, particularly adherence. Improved adherence in later
years likely accounts, in part, for the decrease in the prevalence of a second treatment
failure. Although inclusion of adherence measures would have allowed us to comment more
precisely on the mechanisms accounting for our observations [28], the lack of this
information does not detract from our primary conclusions, which are that multiple regimen
failure is now uncommon, whereas the rate of death after multiple regimen failure remains
high. Finally, because we defined treatment failure on the basis of a single episode of
viremia, it is possible that we included individuals who had an isolated “blip” or whose viral
load was still decreasing. However, most individuals with follow-up data had confirmatory
viral load measurements, and the inferences remained unchanged when censoring those
individuals without confirmed events.
In conclusion, the ability of combination antiretroviral therapy to prevent multiple regimen
failure has improved dramatically over the past decade. Among patients who experience
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multiple regimen failure, mortality rates have also gradually decreased over time. Plasma
HIV RNA levels and CD4+ T cell counts, as well as a history of AIDS, remain independent
risk factors for mortality after multiple regimen failure, which emphasizes that these factors
should be used to target those in need of more-aggressive interventions.
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Study population numbers and selected characteristics. Follow-up reflects time from
initiation of combination therapy to end of follow-up (death or last contributed viral load
measurement [VL]). *Sufficient data was defined as a CD4+ cell count within 1 year before
therapy was switched and at least 1 HIV RNA level obtained after the switch. IQR,
interquartile range.
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Decrease in incidence of second virologic failure over calendar time. The incidence of
second virologic failure (defined as a plasma HIV RNA level >1000 copies/mL) is shown
over time for those individuals who were treatment-naive before receipt of their initial
regimen (dashed line) and those who were treatment-experienced before receipt of their first
regimen (solid line). Vertical bars reflect 95% confidence intervals for the incidence
estimates. Numbers at the bottom display the number of individuals contributing time at-risk
for second virologic failure during each time interval, with the top row indicating the
number of treatment-experienced individuals and the bottom row indicating the number of
treatment-naive individuals. PY, person-years.
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Mortality after second virologic failure by calendar time. The time to death after onset of
second virologic failure (plasma HIV RNA level >1000 copies/mL) was estimated with use
of Kaplan-Meier methods. Individuals were stratified on the basis of the calendar time at
which the second virologic failure was identified.
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Table 3
Predictors of Mortality after Second Virologic Failure using Cox Regression Models with Age as the
Timescale and Stratified by Cohort
Full dataseta Analysis of patients who were antiretroviral
naive before first combination regimenb
Predictor Relative hazard (95%
CI)
P Relative hazard (95% CI) P
Calendar time linear trend (per year) 0.95 (0.92–0.99) <.01 0.91 (0.85–0.98) .01
Female sex 0.81 (0.63–1.04) .10 0.59 (0.33–1.06) .08
History of clinical AIDS 1.40 (1.25–1.56) <.01 1.37 (1.07–1.74) .01
CD4+ T cell count at second virologic failure
    >200 cells/mm3 Reference Reference
    50–200 cells/mm3 1.88 (1.66–2.13) <.01 1.91 (1.45–2.52) <.01
    <50 cells/mm3 4.40 (3.79–5.11) <.01 1.62 (1.21–2.15) <.01
HIV RNA level at second virologic failure
    <10,000 copies/mL Reference Reference
    10,000 to 100,000 copies/mL 1.32 (1.16–1.50) <.01 1.62 (1.21–2.15) <.01
    >100,000 copies/mL 2.05 (1.76–2.37) <.01 2.23 (1.59–3.11) <.01
Type of therapy at initiation of first regimen
    PI based Reference Reference
    NNRTI based 0.99 (0.82–1.22) .99 1.02 (0.71–1.46) .92
    PI or NNRTI 0.99 (0.78–1.25) .91 1.24 (0.79–1.94) .35
    ≥3 NRTIs 0.78 (0.35–1.72) .53 1.02 (0.35–2.98) .97
Treatment experienced before initiation of first
regimen
1.11 (0.98–1.27) .10 NA
NOTE. CI, confidence interval; NA, not applicable; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase
inhibitor; PI, protease inhibitor.
a
There were 1532 deaths among 6698 patients.
b
There were 355 deaths among 2050 patients.
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